{"id":"W2313872863","doi":"10.1158/0008-5472.sabcs11-p1-17-01","title":"P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Exemestane; Medicine; Clinical endpoint; Internal medicine; Interim analysis; Breast cancer; Oncology; Metastatic breast cancer; Randomized controlled trial; Clinical trial; Cancer; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001913992,0.002533065,0.002884314,0.0006080579,0.0003959363,0.001535136,0.001256504,0.001999577,0.00994472],"category_scores_gemma":[0.001649426,0.00098942,0.001753074,0.0005360944,0.001426816,0.001458512,0.0004230175,0.004730746,0.001816547],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009537971,"about_ca_system_score_gemma":0.001745721,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008199672,"about_ca_topic_score_gemma":0.001856583,"domain_scores_codex":[0.9995633,0.0002140896,0.00001959196,0.00008061736,0.00003175728,0.00009063007],"domain_scores_gemma":[0.9991121,0.0002106512,0.0001806553,0.00005222966,0.00003693793,0.0004074235],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.968969,0.01286683,0.0003073714,0.0004642668,0.0003561627,0.00005217274,0.00003914813,0.0003177596,0.00305362,0.0001051177,0.001019233,0.0124493],"study_design_scores_gemma":[0.9273078,0.07082662,0.0005215469,0.00001881071,0.0001486822,0.00003356033,0.00001314619,0.0002918979,0.0003330712,0.00008975028,0.0004068518,0.000008347041],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9793449,0.00410834,0.0006773241,0.001296451,0.001036187,0.00829344,0.002212799,0.0002676462,0.002763063],"genre_scores_gemma":[0.968871,0.004111895,0.002461037,0.001857228,0.001172113,0.01112921,0.002404361,0.00006191229,0.007931231],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00994472,"threshold_uncertainty_score":0.03326833,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1443047070812785,"score_gpt":0.4505939564901019,"score_spread":0.3062892494088234,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}